“Before settling on Jiahui, I received treatment proposals from hospitals in Saudi Arabia and the United States. I chose Jiahui for their prompt replies and efficient communication. This innovative solid‑tumor CAR‑T therapy was also the most accessible option for my condition,” Josh recalled. “I had never visited China before, so I was anxious. Fortunately, I met the Jiahui team, especially Dr. Xuan, who practiced medicine in the United States for two decades.

Recently, the Radiation Therapy Center of Hygeia Chang An Hospital Cancer Hospital has successfully implemented Spatially Fractionated Radiation Therapy (SFRT), benefiting multiple patients with complex tumors. For large‑volume, irregular, refractory recurrent tumors, tumors at special locations adjacent to vital organs and advanced‑stage cancers, this innovative technique can better destroy lesions while safeguarding critical organs.

Independently developed by Sichuan Biokin Pharmaceutical Co., Ltd., Izalontamab Brengitecan for Injection (Iza-Bren) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (bispecific ADC). It received its first NMPA approval in June 2026 for adult patients with recurrent/metastatic nasopharyngeal carcinoma who failed at least two lines of systemic chemotherapy plus PD-1/PD-L1 inhibitors, and previously obtained FDA Breakthrough Therapy Designation.

The earliest pivotal CAR-T trial for R/R DLBCL, utilizing CD19-targeted CAR-T with CD28 costimulatory domain. The ZUMA series has advanced to ZUMA 9 and real-world research, enrolling over 295 patients. Key findings: CD28-based CAR-T triggers rapid, severe cytokine release syndrome (CRS); 32% of patients required ICU admission for CRS. Re-administering identical CAR-T cells to partial response (PR) patients fails to boost efficacy.

Genetic testing is indispensable for hematological disease management. For acute leukemia, it supports diagnosis, prognosis assessment and treatment guidance. However, interpreting genetic mutation reports is highly complex. Clinicians must distinguish germline (inherited) mutations from somatic tumor-derived variants, clarify whether germline variants contribute to leukemia susceptibility, analyze mutation loci, variant combinations, and their impacts on prognosis and target

Wondering why leukemia patients need genetic testing? Director Zheng Qinlong explains its vital role in precision hematology care. Genetic heterogeneity drives varied chemo responses; gene sequencing guides targeted therapy, MRD surveillance and risk stratification. Comprehensive molecular profiling avoids ineffective regimens, cuts costs and enables personalized long-term treatment plans.

In traditional oncology, the "trial-and-error" method has long been a frustrating reality for patients. Clinicians prescribe standard chemotherapy and targeted regimens based on global guidelines.Today, a revolutionary technology known as Organoid Drug Sensitivity Testing is dismantling this paradigm. By cultivating a patient's micro-scale "biological avatar" in the laboratory, clinicians can pre-screen and predict the most effective drug combination before administration.

In the realm of advanced hepatobiliary oncology, a diagnosis of locally advanced, unresectable cholangiocarcinoma—especially with major vascular involvement—has historically been considered a clinical "dead end." However, a recent case from Sir Run Run Shaw Hospital (SRRSH) is challenging this status quo, demonstrating how a "Conversion Therapy" paradigm can successfully redefine treatment boundaries.